Neth Heart J (2015) 23:193
DOI 10.1007/s12471-015-0667-8

LETTER-TO-THE EDITOR

# Chronic thromboembolic pulmonary hypertension

**Michele Correale · Donato Lacedonia · Giovanna D'Andrea · Maurizio Margaglione · Matteo Di Biase · Natale Daniele Brunetti**

Published online: 18 February 2015


We read with great interest the review by Scholzel et al. [1], about chronic thromboembolic pulmonary hypertension (CTEPH), and especially, the sections on pathophysiology, risk factors and diagnostic work-up. However, we would like a further comment about congenital abnormalities causing hypercoagulability in these subjects. In fact, in our experience [2, 3], we have observed CTEPH patients with methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism or combined deficiency of proteins C and S. Can we consider these abnormalities as predisposing factors for CTEPH? Should thrombophilia screening be performed in subjects with suspect PAH?

Could these abnormalities play a role in recurrent pulmonary hypertension after pulmonary endarterectomy?



M. Correale (✉) · M. Di Biase · N. D. Brunetti
Department of Cardiology, University of Foggia,
Viale L Pinto 1,
71100 Foggia, Italy
e-mail: opsfco@tin.it

D. Lacedonia
Institute of Respiratory Disease, Department of Surgical and Medical Sciences, University of Foggia,
Foggia, Italy

G. D'Andrea · M. Margaglione
Department of Clinical and Experimental Medicine,
University of Foggia,
Foggia, Italy

## References

1. Schölzel BE, Snijder RJ, Mager JJ, et al. Chronic thromboembolic pulmonary hypertension. Neth Heart J. 2014;22:533–41.
2. Correale M, Montrone D, Lacedonia D, et al. Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. Monaldi Arch Chest Dis. 2012;78:205–9.
3. D'Amato N, Correale M, D'Agostino C. Aortic thrombus and acute pulmonary embolism in an individual heterozygous for the MTHFR C677T mutation. Rev Esp Cardiol. 2010;63:1366.